FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Vet Sci / The immunomodulation-immunogenicity balance of equine Mesenc...
Frontiers in veterinary science2022; 9; 957153; doi: 10.3389/fvets.2022.957153

The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility.

Abstract: The immunomodulatory properties of equine mesenchymal stem cells (MSCs) are important for their therapeutic potential and for their facilitating role in their escape from immune recognition, which may also be influenced by donor-recipient major histocompatibility complex (MHC) matching/mismatching and MHC expression level. Factors such as inflammation can modify the balance between regulatory and immunogenic profiles of equine MSCs, but little is known about how the exposure to the immune system can affect these properties in equine MSCs. In this study, we analyzed the gene expression and secretion of molecules related to the immunomodulation and immunogenicity of equine MSCs, either non-manipulated (MSC-naive) or stimulated by pro-inflammatory cytokines (MSC-primed), before and after their exposure to autologous or allogeneic MHC-matched/-mismatched lymphocytes, either activated or resting. Cytokine priming induced the immunomodulatory profile of MSCs at the baseline (MSCs cultured alone), and the exposure to activated lymphocytes further increased the expression of , and , and IL6 secretion. Activated lymphocytes were also able to upregulate the regulatory profile of MSC-naive to levels comparable to cytokine priming. On the contrary, resting lymphocytes did not upregulate the immunomodulatory profile of equine MSCs, but interestingly, MSC-primed exposed to MHC-mismatched lymphocytes showed the highest expression and secretion of these mediators, which may be potentially linked to the activation of lymphocytes upon recognition of foreign MHC molecules. Cytokine priming alone did not upregulate the immunogenic genes, but MSC-primed exposed to activated or resting lymphocytes increased their and expression, regardless of the MHC-compatibility. The upregulation of immunogenic markers including in the MHC-mismatched co-culture might have activated lymphocytes, which, at the same time, could have promoted the immune regulatory profile aforementioned. In conclusion, activated lymphocytes are able to induce the equine MSC regulatory profile, and their effects seem to be additive to the priming action. Importantly, our results suggest that the lymphocyte response against MHC-mismatched MSC-primed would promote further activation of their immunomodulatory ability, which eventually might help them evade this reaction. Further studies are needed to clarify how these findings might have clinical implications , which will help developing safer and more effective therapies.
Copyright © 2022 Cequier, Vázquez, Romero, Vitoria, Bernad, García-Martínez, Gascón, Barrachina and Rodellar.
Get Full Text
Publication Date: 2022-10-20 PubMed ID: 36337202PubMed Central: PMC9632425DOI: 10.3389/fvets.2022.957153Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research examines how the immune system response impacts the regulatory and immunogenic properties of horse-derived mesenchymal stem cells (MSCs). It investigates how aspects like inflammation, the presence of pro-inflammatory cytokines and types of major histocompatibility complex (MHC) matching affect these properties.

Immunomodulation and Immunogenicity of MSCs

The researchers analyzed gene expression and secretion of molecules related to immunomodulation and immunogenicity in two types of equine MSCs:

  • The MSCs that had not been manipulated (designated as MSC-naive)
  • The MSCs that had been stimulated by pro-inflammatory cytokines (referred to as MSC-primed)

Before and after their exposure to either autologous (from the same individual) or allogeneic (from a different individual) MHC-matched or MHC-mismatched lymphocytes, these cells were further categorized depending on whether they were activated or resting.

Result of Cytokine Priming

Cytokine priming instigated an immunomodulatory profile in the MSCs. This induced profile was more prominent when the cells were cultured alone. Moreover, exposure to activated lymphocytes increased the expression of immunomodulatory molecules, along with IL6 secretion.

Impact of Lymphocytes on MSCs

  • Activated lymphocytes escalated the regulatory profile of MSC-naive cells, taking them to a level equivalent to cytokine priming.
  • Resting lymphocytes did not augment the immunomodulatory profile of MSCs. However, MSC-primed cells exposed to MHC-mismatched lymphocytes showed a significant increase in the expression and secretion of these cells, which could potentially trigger the activation of lymphocytes on recognizing foreign MHC molecules.

Altered Immunogenicity in MSC-Priming

While cytokine priming alone did not augment immunogenic genes, MSC-primed cells exposed to both activated and resting lymphocytes boosted their immunogenic gene expression, irrespective of MHC-compatibility. Notably, in MHC-mismatched co-culture, the increase in immunogenic markers potentially activated lymphocytes, thereby promoting a regulatory profile.

Findings and Future Research

The crux of the research indicates that activated lymphocytes stimulate the regulatory profile in equine MSCs. This effect is compounded by the action of cytokine priming. More importantly, the researchers shed light on the possibility of further activation of the immunomodulatory ability in MHC-mismatched MSC-primed cells when subjected to a lymphocyte response, which may aid them in evading such reactions. Further studies are essential to clarify the clinical implications of these findings for the development of superior and safer therapeutic interventions.

Cite This Article

APA
Cequier A, Vázquez FJ, Romero A, Vitoria A, Bernad E, García-Martínez M, Gascón I, Barrachina L, Rodellar C. (2022). The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility. Front Vet Sci, 9, 957153. https://doi.org/10.3389/fvets.2022.957153

Publication

Frontiers in veterinary science
ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 9
Pages: 957153
PII: 957153

Researcher Affiliations

Cequier, Alina
  • Laboratorio de Genética Bioquímica LAGENBIO, Instituto de Investigación Sanitaria de Aragón (IIS), Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), Zaragoza, Spain.
  • Servicio de Cirugía y Medicina Equina, Hospital Veterinario, Universidad de Zaragoza, Zaragoza, Spain.
Vázquez, Francisco José
  • Laboratorio de Genética Bioquímica LAGENBIO, Instituto de Investigación Sanitaria de Aragón (IIS), Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), Zaragoza, Spain.
  • Servicio de Cirugía y Medicina Equina, Hospital Veterinario, Universidad de Zaragoza, Zaragoza, Spain.
Romero, Antonio
  • Laboratorio de Genética Bioquímica LAGENBIO, Instituto de Investigación Sanitaria de Aragón (IIS), Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), Zaragoza, Spain.
  • Servicio de Cirugía y Medicina Equina, Hospital Veterinario, Universidad de Zaragoza, Zaragoza, Spain.
Vitoria, Arantza
  • Laboratorio de Genética Bioquímica LAGENBIO, Instituto de Investigación Sanitaria de Aragón (IIS), Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), Zaragoza, Spain.
  • Servicio de Cirugía y Medicina Equina, Hospital Veterinario, Universidad de Zaragoza, Zaragoza, Spain.
Bernad, Elvira
  • Laboratorio de Genética Bioquímica LAGENBIO, Instituto de Investigación Sanitaria de Aragón (IIS), Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), Zaragoza, Spain.
García-Martínez, Mirta
  • Laboratorio de Genética Bioquímica LAGENBIO, Instituto de Investigación Sanitaria de Aragón (IIS), Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), Zaragoza, Spain.
Gascón, Isabel
  • Laboratorio de Genética Bioquímica LAGENBIO, Instituto de Investigación Sanitaria de Aragón (IIS), Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), Zaragoza, Spain.
Barrachina, Laura
  • Laboratorio de Genética Bioquímica LAGENBIO, Instituto de Investigación Sanitaria de Aragón (IIS), Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), Zaragoza, Spain.
  • Servicio de Cirugía y Medicina Equina, Hospital Veterinario, Universidad de Zaragoza, Zaragoza, Spain.
Rodellar, Clementina
  • Laboratorio de Genética Bioquímica LAGENBIO, Instituto de Investigación Sanitaria de Aragón (IIS), Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), Zaragoza, Spain.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

This article includes 59 references
  1. Cequier A, Sanz C, Rodellar C, Barrachina L. The Usefulness of Mesenchymal Stem Cells beyond the Musculoskeletal System in Horses.. Animals (Basel) 2021 Mar 25;11(4).
    doi: 10.3390/ani11040931pmc: PMC8064371pubmed: 33805967google scholar: lookup
  2. Ribitsch I, Baptista PM, Lange-Consiglio A, Melotti L, Patruno M, Jenner F, Schnabl-Feichter E, Dutton LC, Connolly DJ, van Steenbeek FG, Dudhia J, Penning LC. Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do.. Front Bioeng Biotechnol 2020;8:972.
    doi: 10.3389/fbioe.2020.00972pmc: PMC7438731pubmed: 32903631google scholar: lookup
  3. Hillmann A, Paebst F, Brehm W, Piehler D, Schubert S, Tárnok A, Burk J. A novel direct co-culture assay analyzed by multicolor flow cytometry reveals context- and cell type-specific immunomodulatory effects of equine mesenchymal stromal cells.. PLoS One 2019;14(6):e0218949.
    doi: 10.1371/journal.pone.0218949pmc: PMC6597077pubmed: 31247035google scholar: lookup
  4. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().. Cell Med 2012;4(1):1-11.
    doi: 10.3727/215517912X647217pmc: PMC3495591pubmed: 23152950google scholar: lookup
  5. Berglund AK, Long JM, Robertson JB, Schnabel LV. TGF-β2 Reduces the Cell-Mediated Immunogenicity of Equine MHC-Mismatched Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Immunomodulatory Properties.. Front Cell Dev Biol 2021;9:628382.
    doi: 10.3389/fcell.2021.628382pmc: PMC7889809pubmed: 33614658google scholar: lookup
  6. Berglund AK, Fortier LA, Antczak DF, Schnabel LV. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells.. Stem Cell Res Ther 2017 Dec 22;8(1):288.
    doi: 10.1186/s13287-017-0742-8pmc: PMC5741939pubmed: 29273086google scholar: lookup
  7. Kamm JL, Riley CB, Parlane NA, Gee EK, McIlwraith CW. Immune response to allogeneic equine mesenchymal stromal cells.. Stem Cell Res Ther 2021 Nov 12;12(1):570.
    doi: 10.1186/s13287-021-02624-ypmc: PMC8588742pubmed: 34772445google scholar: lookup
  8. Barrachina L, Cequier A, Romero A, Vitoria A, Zaragoza P, Vázquez FJ, Rodellar C. Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility.. Stem Cell Res Ther 2020 Feb 7;11(1):52.
    doi: 10.1186/s13287-020-1571-8pmc: PMC7006079pubmed: 32028995google scholar: lookup
  9. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.. Stem Cell Res Ther 2014 Jan 24;5(1):13.
    doi: 10.1186/scrt402pmc: PMC4055004pubmed: 24461709google scholar: lookup
  10. Rowland AL, Xu JJ, Joswig AJ, Gregory CA, Antczak DF, Cummings KJ, Watts AE. In vitro MSC function is related to clinical reaction in vivo.. Stem Cell Res Ther 2018 Nov 8;9(1):295.
    doi: 10.1186/s13287-018-1037-4pmc: PMC6225557pubmed: 30409211google scholar: lookup
  11. Isakova IA, Lanclos C, Bruhn J, Kuroda MJ, Baker KC, Krishnappa V, Phinney DG. Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo.. PLoS One 2014;9(1):e87238.
    doi: 10.1371/journal.pone.0087238pmc: PMC3906169pubmed: 24489878google scholar: lookup
  12. García-Sancho J, Sánchez A, Vega A, Noriega DC, Nocito M. Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease.. Transplant Direct 2017 Sep;3(9):e205.
    doi: 10.1097/TXD.0000000000000724pmc: PMC5585421pubmed: 28894792google scholar: lookup
  13. Barrachina L, Remacha AR, Romero A, Vitoria A, Albareda J, Prades M, Roca M, Zaragoza P, Vázquez FJ, Rodellar C. Assessment of effectiveness and safety of repeat administration of proinflammatory primed allogeneic mesenchymal stem cells in an equine model of chemically induced osteoarthritis.. BMC Vet Res 2018 Aug 17;14(1):241.
    doi: 10.1186/s12917-018-1556-3pmc: PMC6098603pubmed: 30119668google scholar: lookup
  14. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged.. Nat Biotechnol 2014 Mar;32(3):252-60.
    doi: 10.1038/nbt.2816pmc: PMC4320647pubmed: 24561556google scholar: lookup
  15. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Gosálvez J, Roy R, Zaragoza P, Martín-Burriel I, Rodellar C. Priming Equine Bone Marrow-Derived Mesenchymal Stem Cells with Proinflammatory Cytokines: Implications in Immunomodulation-Immunogenicity Balance, Cell Viability, and Differentiation Potential.. Stem Cells Dev 2017 Jan 1;26(1):15-24.
    doi: 10.1089/scd.2016.0209pubmed: 27712399google scholar: lookup
  16. Cequier A, Romero A, Vázquez FJ, Vitoria A, Bernad E, Fuente S, Zaragoza P, Rodellar C, Barrachina L. Equine Mesenchymal Stem Cells Influence the Proliferative Response of Lymphocytes: Effect of Inflammation, Differentiation and MHC-Compatibility.. Animals (Basel) 2022 Apr 11;12(8).
    doi: 10.3390/ani12080984pmc: PMC9031781pubmed: 35454231google scholar: lookup
  17. Sadeghi R, Moradi-Shahrbabak M, Miraei Ashtiani SR, Miller DC, Antczak DF. MHC haplotype diversity in Persian Arabian horses determined using polymorphic microsatellites.. Immunogenetics 2018 May;70(5):305-315.
    doi: 10.1007/s00251-017-1039-xpubmed: 29170799google scholar: lookup
  18. Holmes CM, Violette N, Miller D, Wagner B, Svansson V, Antczak DF. MHC haplotype diversity in Icelandic horses determined by polymorphic microsatellites.. Genes Immun 2019 Nov;20(8):660-670.
    doi: 10.1038/s41435-019-0075-ypubmed: 31068686google scholar: lookup
  19. Barrachina L, Cequier A, Vitoria A, Cons C, Sanz A, Zaragoza P. Determination of MHC haplotypes in pure-breed Spanish horses using microsatellites. In: 37th International Society for Animal Genetics Conference. Lleida: (2019). p. 33.
  20. Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types.. Cell Stem Cell 2012 Aug 3;11(2):147-52.
    doi: 10.1016/j.stem.2012.07.014pubmed: 22862941google scholar: lookup
  21. Sullivan S, Ginty P, McMahon S, May M, Solomon SL, Kurtz A, Stacey GN, Bennaceur Griscelli A, Li RA, Barry J, Song J, Turner ML. The Global Alliance for iPSC Therapies (GAiT).. Stem Cell Res 2020 Dec;49:102036.
    doi: 10.1016/j.scr.2020.102036pubmed: 33212350google scholar: lookup
  22. Rowland AL, Miller D, Berglund A, Schnabel LV, Levine GJ, Antczak DF, Watts AE. Cross-matching of allogeneic mesenchymal stromal cells eliminates recipient immune targeting.. Stem Cells Transl Med 2021 May;10(5):694-710.
    doi: 10.1002/sctm.20-0435pmc: PMC8046071pubmed: 33369287google scholar: lookup
  23. Berglund AK, Schnabel LV. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.. Equine Vet J 2017 Jul;49(4):539-544.
    doi: 10.1111/evj.12647pmc: PMC5425313pubmed: 27862236google scholar: lookup
  24. Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.. Stem Cell Res Ther 2015 Apr 12;6(1):54.
    doi: 10.1186/s13287-015-0053-xpmc: PMC4414005pubmed: 25889095google scholar: lookup
  25. Lepage SIM, Lee OJ, Koch TG. Equine Cord Blood Mesenchymal Stromal Cells Have Greater Differentiation and Similar Immunosuppressive Potential to Cord Tissue Mesenchymal Stromal Cells.. Stem Cells Dev 2019 Feb 1;28(3):227-237.
    doi: 10.1089/scd.2018.0135pubmed: 30484372google scholar: lookup
  26. Colbath AC, Dow SW, Phillips JN, McIlwraith CW, Goodrich LR. Autologous and Allogeneic Equine Mesenchymal Stem Cells Exhibit Equivalent Immunomodulatory Properties In Vitro.. Stem Cells Dev 2017 Apr 1;26(7):503-511.
    doi: 10.1089/scd.2016.0266pubmed: 27958776google scholar: lookup
  27. Remacha AR, Barrachina L, Álvarez-Arguedas S, Ranera B, Romero A, Vázquez FJ, Zaragoza P, Yañez R, Martín-Burriel I, Rodellar C. Expression of genes involved in immune response and in vitro immunosuppressive effect of equine MSCs.. Vet Immunol Immunopathol 2015 Jun 15;165(3-4):107-18.
    doi: 10.1016/j.vetimm.2015.04.004pubmed: 25977164google scholar: lookup
  28. Ranera B, Antczak D, Miller D, Doroshenkova T, Ryan A, McIlwraith CW, Barry F. Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes.. Equine Vet J 2016 Mar;48(2):253-60.
    doi: 10.1111/evj.12414pubmed: 25582202google scholar: lookup
  29. Paterson YZ, Rash N, Garvican ER, Paillot R, Guest DJ. Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro.. Stem Cell Res Ther 2014 Jul 30;5(4):90.
    doi: 10.1186/scrt479pmc: PMC4247727pubmed: 25080326google scholar: lookup
  30. Carrade Holt DD, Wood JA, Granick JL, Walker NJ, Clark KC, Borjesson DL. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source.. Stem Cells Dev 2014 Jun 1;23(11):1258-65.
    doi: 10.1089/scd.2013.0537pubmed: 24438346google scholar: lookup
  31. Clark KC, Kol A, Shahbenderian S, Granick JL, Walker NJ, Borjesson DL. Canine and Equine Mesenchymal Stem Cells Grown in Serum Free Media Have Altered Immunophenotype.. Stem Cell Rev Rep 2016 Apr;12(2):245-56.
    doi: 10.1007/s12015-015-9638-0pmc: PMC4841858pubmed: 26638159google scholar: lookup
  32. Cassano JM, Schnabel LV, Goodale MB, Fortier LA. The immunomodulatory function of equine MSCs is enhanced by priming through an inflammatory microenvironment or TLR3 ligand.. Vet Immunol Immunopathol 2018 Jan;195:33-39.
    doi: 10.1016/j.vetimm.2017.10.003pubmed: 29249315google scholar: lookup
  33. Cassano JM, Fortier LA, Hicks RB, Harman RM, Van de Walle GR. Equine mesenchymal stromal cells from different tissue sources display comparable immune-related gene expression profiles in response to interferon gamma (IFN)-γ.. Vet Immunol Immunopathol 2018 Aug;202:25-30.
    doi: 10.1016/j.vetimm.2018.06.008pubmed: 30078595google scholar: lookup
  34. Cagliani J, Grande D, Molmenti EP, Miller EJ, Rilo HLR. Immunomodulation by Mesenchymal Stromal Cells and Their Clinical Applications.. J Stem Cell Regen Biol 2017;3(2).
    doi: 10.15436/2471-0598.17.022pmc: PMC5667922pubmed: 29104965google scholar: lookup
  35. De Schauwer C, Goossens K, Piepers S, Hoogewijs MK, Govaere JL, Smits K, Meyer E, Van Soom A, Van de Walle GR. Characterization and profiling of immunomodulatory genes of equine mesenchymal stromal cells from non-invasive sources.. Stem Cell Res Ther 2014 Jan 13;5(1):6.
    doi: 10.1186/scrt395pmc: PMC4055120pubmed: 24418262google scholar: lookup
  36. Cassano JM, Schnabel LV, Goodale MB, Fortier LA. Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment.. Stem Cell Res Ther 2018 Apr 3;9(1):82.
    doi: 10.1186/s13287-018-0840-2pmc: PMC5883371pubmed: 29615127google scholar: lookup
  37. Foo JB, Looi QH, Chong PP, Hassan NH, Yeo GEC, Ng CY, Koh B, How CW, Lee SH, Law JX. Comparing the Therapeutic Potential of Stem Cells and their Secretory Products in Regenerative Medicine.. Stem Cells Int 2021;2021:2616807.
    doi: 10.1155/2021/2616807pmc: PMC8378970pubmed: 34422061google scholar: lookup
  38. Alvites R, Branquinho M, Sousa AC, Lopes B, Sousa P, Maurício AC. Mesenchymal Stem/Stromal Cells and Their Paracrine Activity-Immunomodulation Mechanisms and How to Influence the Therapeutic Potential.. Pharmaceutics 2022 Feb 9;14(2).
    doi: 10.3390/pharmaceutics14020381pmc: PMC8875256pubmed: 35214113google scholar: lookup
  39. Han Y, Yang J, Fang J, Zhou Y, Candi E, Wang J, Hua D, Shao C, Shi Y. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases.. Signal Transduct Target Ther 2022 Mar 21;7(1):92.
    doi: 10.1038/s41392-022-00932-0pmc: PMC8935608pubmed: 35314676google scholar: lookup
  40. Su J, Chen X, Huang Y, Li W, Li J, Cao K, Cao G, Zhang L, Li F, Roberts AI, Kang H, Yu P, Ren G, Ji W, Wang Y, Shi Y. Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species.. Cell Death Differ 2014 Mar;21(3):388-96.
    doi: 10.1038/cdd.2013.149pmc: PMC3921585pubmed: 24162664google scholar: lookup
  41. Wu H, Gong J, Liu Y. Indoleamine 2, 3-dioxygenase regulation of immune response (Review).. Mol Med Rep 2018 Apr;17(4):4867-4873.
    doi: 10.3892/mmr.2018.8537pubmed: 29393500google scholar: lookup
  42. Caffi V, Espinosa G, Gajardo G, Morales N, Durán MC, Uberti B, Morán G, Plaza A, Henríquez C. Pre-conditioning of Equine Bone Marrow-Derived Mesenchymal Stromal Cells Increases Their Immunomodulatory Capacity.. Front Vet Sci 2020;7:318.
    doi: 10.3389/fvets.2020.00318pmc: PMC7325884pubmed: 32656251google scholar: lookup
  43. Pourgholaminejad A, Aghdami N, Baharvand H, Moazzeni SM. The effect of pro-inflammatory cytokines on immunophenotype, differentiation capacity and immunomodulatory functions of human mesenchymal stem cells.. Cytokine 2016 Sep;85:51-60.
    doi: 10.1016/j.cyto.2016.06.003pubmed: 27288632google scholar: lookup
  44. Kamm JL, Riley CB, Parlane N, Gee EK, McIlwraith CW. Interactions Between Allogeneic Mesenchymal Stromal Cells and the Recipient Immune System: A Comparative Review With Relevance to Equine Outcomes.. Front Vet Sci 2020;7:617647.
    doi: 10.3389/fvets.2020.617647pmc: PMC7838369pubmed: 33521090google scholar: lookup
  45. Murphy K. The induced responses of innate immunity. In:Murphy K, Travers P, Walport M, Mowat A, Weaven CS. editors. Janeways Immunobiology. 8th ed. New York, NY: Garland Science; (2012). p. 75–98.
  46. Haddad R, Saldanha-Araujo F. Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: what do we know so far?. Biomed Res Int 2014;2014:216806.
    doi: 10.1155/2014/216806pmc: PMC4082893pubmed: 25025040google scholar: lookup
  47. Berglund AK, Fisher MB, Cameron KA, Poole EJ, Schnabel LV. Transforming Growth Factor-β2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers.. Front Vet Sci 2017;4:84.
    doi: 10.3389/fvets.2017.00084pmc: PMC5466990pubmed: 28660198google scholar: lookup
  48. Kamm JL, Parlane NA, Riley CB, Gee EK, Dittmer KE, McIlwraith CW. Blood type and breed-associated differences in cell marker expression on equine bone marrow-derived mesenchymal stem cells including major histocompatibility complex class II antigen expression.. PLoS One 2019;14(11):e0225161.
    doi: 10.1371/journal.pone.0225161pmc: PMC6867698pubmed: 31747418google scholar: lookup
  49. Lee HJ, Jung H, Kim DK. IDO and CD40 May Be Key Molecules for Immunomodulatory Capacity of the Primed Tonsil-Derived Mesenchymal Stem Cells.. Int J Mol Sci 2021 May 28;22(11).
    doi: 10.3390/ijms22115772pmc: PMC8198434pubmed: 34071285google scholar: lookup
  50. Buyl K, Merimi M, Rodrigues RM, Moussa Agha D, Melki R, Vanhaecke T, Bron D, Lewalle P, Meuleman N, Fahmi H, Rogiers V, Lagneaux L, De Kock J, Najar M. The Impact of Cell-Expansion and Inflammation on The Immune-Biology of Human Adipose Tissue-Derived Mesenchymal Stromal Cells.. J Clin Med 2020 Mar 4;9(3).
    doi: 10.3390/jcm9030696pmc: PMC7141238pubmed: 32143473google scholar: lookup
  51. Briones J, Novelli S, Sierra J. T-cell costimulatory molecules in acute-graft-versus host disease: therapeutic implications.. Bone Marrow Res 2011;2011:976793.
    doi: 10.1155/2011/976793pmc: PMC3195325pubmed: 22046574google scholar: lookup
  52. Wi H, Lee S, Kim Y, No JG, Lee P, Lee BR, Oh KB, Hur TY, Ock SA. Immunosuppression-enhancing effect of the administration of allogeneic canine adipose-derived mesenchymal stem cells (cA-MSCs) compared with autologous cA-MSCs in vitro.. J Vet Sci 2021 Sep;22(5):e63.
    doi: 10.4142/jvs.2021.22.e63pmc: PMC8460457pubmed: 34423601google scholar: lookup
  53. Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W, Roberts AI, Le AD, Shi S, Shao C, Shi Y. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression.. J Immunol 2010 Mar 1;184(5):2321-8.
    doi: 10.4049/jimmunol.0902023pmc: PMC2881946pubmed: 20130212google scholar: lookup
  54. Connard SS, Linardi RL, Even KM, Berglund AK, Schnabel LV, Ortved KF. Effects of continuous passage on the immunomodulatory properties of equine bone marrow-derived mesenchymal stem cells in vitro.. Vet Immunol Immunopathol 2021 Apr;234:110203.
    doi: 10.1016/j.vetimm.2021.110203pubmed: 33636546google scholar: lookup
  55. Saul MJ, Emmerich AC, Steinhilber D, Suess B. Regulation of Eicosanoid Pathways by MicroRNAs.. Front Pharmacol 2019;10:824.
    doi: 10.3389/fphar.2019.00824pmc: PMC6659501pubmed: 31379585google scholar: lookup
  56. Ozdemir AT, Oztatlici M, Ozgul Ozdemir RB, Cakir B, Ozbilgin K, Dariverenli E. The effects of preconditioning with IFN-γ, IL-4 and IL-10 on costimulatory ligand expressions of mesenchymal stem cells. Int J Med Biochem (2021) 4:121–30.
    doi: 10.14744/ijmb.2021.77487google scholar: lookup
  57. van Megen KM, van 't Wout ET, Lages Motta J, Dekker B, Nikolic T, Roep BO. Activated Mesenchymal Stromal Cells Process and Present Antigens Regulating Adaptive Immunity.. Front Immunol 2019;10:694.
    doi: 10.3389/fimmu.2019.00694pmc: PMC6457321pubmed: 31001285google scholar: lookup
  58. Sareen N, Abu-El-Rub E, Ammar HI, Yan W, Sequiera GL, ShamsEldeen AM, Moudgil M, Dhingra R, Shokry HS, Rashed LA, Kirshenbaum LA, Dhingra S. Hypoxia-induced downregulation of cyclooxygenase 2 leads to the loss of immunoprivilege of allogeneic mesenchymal stem cells.. FASEB J 2020 Nov;34(11):15236-15251.
    doi: 10.1096/fj.202001478Rpubmed: 32959405google scholar: lookup
  59. Melief SM, Schrama E, Brugman MH, Tiemessen MM, Hoogduijn MJ, Fibbe WE, Roelofs H. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages.. Stem Cells 2013 Sep;31(9):1980-91.
    doi: 10.1002/stem.1432pubmed: 23712682google scholar: lookup

Citations

This article has been cited 12 times.
  1. Najar M, Fahmi H, Merimi M. The Medicinal Potential of Mesenchymal Stem/Stromal Cells in Immuno- and Cancer Therapy. Biomolecules 2023 Jul 27;13(8).
    doi: 10.3390/biom13081171pubmed: 37627236google scholar: lookup
  2. Donato L, Scimone C, Alibrandi S, Scalinci SZ, Mordà D, Rinaldi C, D'Angelo R, Sidoti A. Human retinal secretome: A cross-link between mesenchymal and retinal cells. World J Stem Cells 2023 Jul 26;15(7):665-686.
    doi: 10.4252/wjsc.v15.i7.665pubmed: 37545752google scholar: lookup
  3. Shahid MA, Guitart AS, Bertin FR, Simon O, Ceusters J, Serteyn D, Whitworth DJ. Characterization and priming of equine muscle-derived mesenchymal stem cells to enhance their anti-inflammatory and immunomodulatory profiles. Front Vet Sci 2025;12:1741322.
    doi: 10.3389/fvets.2025.1741322pubmed: 41602612google scholar: lookup
  4. Rossello-Gelabert M, Heras KL, Gonzalez-Pujana A, Igartua M, Santos-Vizcaino E, Hernandez RM. Immortalized human hair follicle-derived mesenchymal-like stromal cells for the long-term production of scalable Immunomodulatory and regenerative secretome. Stem Cell Res Ther 2025 Nov 17;16(1):643.
    doi: 10.1186/s13287-025-04775-8pubmed: 41250229google scholar: lookup
  5. Dashti M, Mohammaddust Sarab M, Shad F, Dehnavi S. CRISPR-mediated engineering of mesenchymal stromal/stem cells: a summary of recent progress in immunological applications for regenerative medicine and cancer therapy. Stem Cell Res Ther 2025 Oct 29;16(1):592.
    doi: 10.1186/s13287-025-04723-6pubmed: 41163074google scholar: lookup
  6. Yaneselli K, Ávila G, Rossi A, Rial A, Castro S, Estradé MJ, Suárez G, Algorta A. Impact of different formulations of platelet lysate on proliferative and immune profile of equine mesenchymal stromal cells. Front Vet Sci 2024;11:1410855.
    doi: 10.3389/fvets.2024.1410855pubmed: 39161460google scholar: lookup
  7. Cequier A, Vázquez FJ, Vitoria A, Bernad E, Fuente S, Serrano MB, Zaragoza MP, Romero A, Rodellar C, Barrachina L. The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility: in vivo study in the horse. Front Vet Sci 2024;11:1391872.
    doi: 10.3389/fvets.2024.1391872pubmed: 38957800google scholar: lookup
  8. Moellerberndt J, Niebert S, Fey K, Hagen A, Burk J. Impact of platelet lysate on immunoregulatory characteristics of equine mesenchymal stromal cells. Front Vet Sci 2024;11:1385395.
    doi: 10.3389/fvets.2024.1385395pubmed: 38725585google scholar: lookup
  9. Najar M, Bouhtit F, Rahmani S, Bouali A, Melki R, Najimi M, Lewalle P, Merimi M. The immunogenic profile and immunomodulatory function of mesenchymal stromal / stem cells in the presence of Ptychotis verticillata. Heliyon 2024 Feb 15;10(3):e24822.
    doi: 10.1016/j.heliyon.2024.e24822pubmed: 38317994google scholar: lookup
  10. Hwang S, Sung DK, Kim YE, Yang M, Ahn SY, Sung SI, Chang YS. Mesenchymal Stromal Cells Primed by Toll-like Receptors 3 and 4 Enhanced Anti-Inflammatory Effects against LPS-Induced Macrophages via Extracellular Vesicles. Int J Mol Sci 2023 Nov 13;24(22).
    doi: 10.3390/ijms242216264pubmed: 38003458google scholar: lookup
  11. Jammes M, Contentin R, Audigié F, Cassé F, Galéra P. Effect of pro-inflammatory cytokine priming and storage temperature of the mesenchymal stromal cell (MSC) secretome on equine articular chondrocytes. Front Bioeng Biotechnol 2023;11:1204737.
    doi: 10.3389/fbioe.2023.1204737pubmed: 37720315google scholar: lookup
  12. Paganelli A, Diomede F, Marconi GD, Pizzicannella J, Rajan TS, Trubiani O, Paganelli R. Inhibition of LPS-Induced Inflammatory Response of Oral Mesenchymal Stem Cells in the Presence of Galectin-3. Biomedicines 2023 May 24;11(6).
    doi: 10.3390/biomedicines11061519pubmed: 37371614google scholar: lookup
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.